相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab
Heinz Wiendl et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis
Wendy Gilmore et al.
JOURNAL OF NEUROINFLAMMATION (2020)
Monocytes and Monocyte-Derived Antigen-Presenting Cells Have Distinct Gene Signatures in Experimental Model of Multiple Sclerosis
Kelly L. Monaghan et al.
FRONTIERS IN IMMUNOLOGY (2019)
NK cells in autoimmune diseases: Linking innate and adaptive immune responses
Elena Gianchecchi et al.
AUTOIMMUNITY REVIEWS (2018)
Alemtuzumab as Treatment for Multiple Sclerosis
Serafeim Katsavos et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Regulatory T Cells: From Discovery to Autoimmunity
Alexandra Kitz et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis
Yeseul Kim et al.
JOURNAL OF NEUROINFLAMMATION (2018)
Human regulatory B cells in health and disease: therapeutic potential
Claudia Mauri et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Alemtuzumab CARE-MS II 5-year follow-up
Alasdair J. Coles et al.
NEUROLOGY (2017)
Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
David Baker et al.
JAMA NEUROLOGY (2017)
Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
Tjalf Ziemssen et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2017)
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
David Baker et al.
EBIOMEDICINE (2017)
Direct control of B cells by Tregs: An opportunity for long-term modulation of the humoral response
Elizabeth Weingartner et al.
CELLULAR IMMUNOLOGY (2017)
Monocyte differentiation and antigen-presenting functions
Claudia V. Jakubzick et al.
NATURE REVIEWS IMMUNOLOGY (2017)
B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+Lymphocytes Modulate Disease Severity
Federica Piancone et al.
SCIENTIFIC REPORTS (2016)
Natural Regulators: NK Cells as Modulators of T Cell immunity
Iona S. Schuster et al.
FRONTIERS IN IMMUNOLOGY (2016)
Alemtuzumab long-term immunologic effect Treg suppressor function increases up to 24 months
Stefania De Mercanti et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
Catharina C. Gross et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry
Saskia J. A. M. Santegoets et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Natural killer T cells in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis
Luc Van Kaer et al.
IMMUNOLOGY (2015)
The expanding family of regulatory B cells
Claudia Mauri et al.
INTERNATIONAL IMMUNOLOGY (2015)
B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions
Nele Claes et al.
FRONTIERS IN IMMUNOLOGY (2015)
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
Orla Tuohy et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Fingolimod treatment promotes regulatory phenotype and function of B cells
Berit Gruetzke et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations
Yusei Miyazaki et al.
CLINICAL IMMUNOLOGY (2014)
Mode of action and clinical studies with alemtuzumab
Joanne L. Jones et al.
EXPERIMENTAL NEUROLOGY (2014)
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro
Evis Havari et al.
IMMUNOLOGY (2014)
Differential effects of fingolimod on B-cell populations in multiple sclerosis
Masakazu Nakamura et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity
Onajite Kousin-Ezewu et al.
NEUROLOGY (2014)
Regulatory B cells in autoimmune diseases
Min Yang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2013)
Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis
Xin Zhang et al.
JOURNAL OF IMMUNOLOGY (2013)
Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod
Brett T. Lund et al.
JOURNAL OF NEUROIMMUNOLOGY (2013)
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis
Mark D. Cossburn et al.
NEUROLOGY (2013)
Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation
Joanne L. Jones et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
CD19+CD24hiCD38hi B Cells Maintain Regulatory T Cells While Limiting TH1 and TH17 Differentiation
Fabian Flores-Borja et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
B Cell Repopulation After Alemtuzumab Induction - Transient Increase in Transitional B Cells and Long-Term Dominance of Naive B Cells
S. Heidt et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Immune Regulatory Function of B Cells
Claudia Mauri et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
Grant A. Hill-Cawthorne et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity
Joanne L. Jones et al.
BRAIN (2010)
Alternative Activation of Macrophages: Mechanism and Functions
Siamon Gordon et al.
IMMUNITY (2010)
B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
Sara A. J. Thompson et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
Crosstalk between decidual NK and CD14+ myelomonocytic cells results in induction of Tregs and immunosuppression
Paola Vacca et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Alternative Activation of Macrophages: An Immunologic Functional Perspective
Fernando O. Martinez et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab
Lyn R. Ambrose et al.
BLOOD (2009)
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Josa M. Frischer et al.
BRAIN (2009)
Antigen presentation by monocytes and monocyte-derived cells
Gwendalyn J. Randolph et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis
Alasdair J. Coles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis
Manoj Kumar et al.
JOURNAL OF NEUROIMMUNOLOGY (2006)
Autoimmunity during lymphopenia: A two-hit model
Tom Krupica et al.
CLINICAL IMMUNOLOGY (2006)
CD4+CD25+ Tregs and NKT cells:: regulators regulating regulators
Antonio La Cava et al.
TRENDS IN IMMUNOLOGY (2006)
Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis
LA Boven et al.
BRAIN (2006)
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis
AL Cox et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Decreased FOXP3 levels in multiple sclerosis patients
J Huan et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2005)
A causal link between lymphopenia and autoimmunity
A Khoruts et al.
IMMUNOLOGY LETTERS (2005)
Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis
V Viglietta et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis
HJ Kim et al.
JOURNAL OF IMMUNOLOGY (2004)
CCR1+/CCR5+mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis
C Trebst et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
分享论文
